Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Tenaya Therapeutics Inc’s stock clocked out at $1.6, down -4.76% from its previous closing price of $1.68. In other words, the price has decreased by -$4.76 from its previous closing price. On the day, 2.89 million shares were traded. TNYA stock price reached its highest trading level at $1.71 during the session, while it also had its lowest trading level at $1.6.
Ratios:
To gain a deeper understanding of TNYA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.00 and its Current Ratio is at 6.00. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 30, 2023, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On June 15, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on June 15, 2022, with a $25 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Higa Tomohiro sold 2,962 shares for $1.25 per share. The transaction valued at 3,711 led to the insider holds 95,338 shares of the business.
Tingley Whittemore sold 5,053 shares of TNYA for $6,331 on Aug 18 ’25. The Chief Medical Officer now owns 172,803 shares after completing the transaction at $1.25 per share. On Aug 18 ’25, another insider, Ali Faraz, who serves as the Chief Executive Officer of the company, sold 14,533 shares for $1.25 each. As a result, the insider received 18,210 and left with 302,792 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNYA now has a Market Capitalization of 260761760 and an Enterprise Value of 201304768.
Stock Price History:
The Beta on a monthly basis for TNYA is 3.16, which has changed by -0.096045196 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, TNYA has reached a high of $4.01, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is 42.31%, while the 200-Day Moving Average is calculated to be 78.69%.
Shares Statistics:
It appears that TNYA traded 3.23M shares on average per day over the past three months and 3601750 shares per day over the past ten days. A total of 162.98M shares are outstanding, with a floating share count of 137.66M. Insiders hold about 15.53% of the company’s shares, while institutions hold 18.01% stake in the company. Shares short for TNYA as of 1757894400 were 15047000 with a Short Ratio of 4.66, compared to 1755216000 on 11919989. Therefore, it implies a Short% of Shares Outstanding of 15047000 and a Short% of Float of 25.36.
Earnings Estimates
Tenaya Therapeutics Inc (TNYA) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.07 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.58 and -$0.81 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.6, with 6.0 analysts recommending between -$0.51 and -$0.73.
